Clinical Trial: A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876414) titled 'A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.' on Oct. 09.

Brief Summary: The objective of this research is to evaluate the efficacy of the new drug INCA33890 compared to the standard reference treatment, pembrolizumab.

The study treatment is INCA33890. The reference treatment is pembrolizumab. Two-thirds of participants will receive INCA33890, and one-third will receive pembrolizumab.

The details for the different treatment groups are as follows:

* Group A: You will receive INCA33890 (900 mg) every two weeks for 3 cycles.

* Group B: You will receive pem...